Browsing Tag
Stéphane Bancel
10 posts
Moderna proposes $2bn zero-coupon notes as oncology success reshapes capital strategy
Moderna plans a $2 billion private placement of zero-regular-interest convertible notes due 2032, with a possible additional $300 million and capped-call protection designed to reduce dilution as the company prepares for increased oncology investment.
Moderna faces fresh mRNA patent assault from CureVac as BioNTech tightens legal grip on COVID-19 vaccine royalties
Moderna just settled $950 million in mRNA litigation. Now BioNTech-owned CureVac wants Spikevax royalties too. The patent war is widening.
Moderna to acquire Japanese biotech firm OriCiro Genomics for $85m
Moderna has agreed to acquire OriCiro Genomics, a Japanese biotech firm involved in developing cell-free synthesis and amplification…
Moderna to build mRNA vaccine manufacturing plant in Victoria
Moderna has signed an agreement in principle with the Government of Australia to build a messenger RNA (mRNA)…
US biotech company Moderna to build $500m mRNA facility in Africa
Moderna will invest up to $500 million to construct a messenger RNA facility (mRNA facility) in Africa with…
Indian government approves use of Moderna’s Covid-19 Vaccine Moderna
US biotech company Moderna has been given emergency use authorization from the Indian government for its Covid-19 Vaccine…
Moderna to supply 7m more doses of Covid-19 Vaccine Moderna to Philippines
Moderna has agreed to supply the Philippines with seven million additional doses of Covid-19 Vaccine Moderna, to take…
FDA grants emergency use authorization for Moderna’s Covid-19 vaccine: What this means for the U.S. pandemic response
Find out how Moderna’s mRNA-1273 vaccine received FDA emergency use authorization and what it means for the United States’ Covid-19 vaccination rollout.
Moderna bags $1.5bn contract to supply mRNA-1273 Covid-19 vaccine to US govt
Moderna has bagged a deal worth up to $1.52 billion for the manufacturing and supply of 100 million…
Coronavirus vaccine trial results : Moderna mRNA-1273 shows early promise
Moderna said that mRNA-1273, its novel coronavirus vaccine candidate, has delivered positive interim data in a phase 1…